Last updated: May 3, 2026
What is PHENERGAN VC and how is it positioned clinically?
PHENERGAN VC is a branded formulation of promethazine hydrochloride combined with vitamin C (ascorbic acid), marketed for symptomatic relief of conditions where an antihistamine plus vitamin C is used. Promethazine is an established first-generation antihistamine with sedating and antiemetic activity, historically used for nausea, allergic symptoms, and related symptomatic care. Vitamin C is used as an adjunct component in marketed “immune support” and general supplementation products.
Clinical evidence and regulatory documentation for PHENERGAN VC itself depends on the specific country’s brand registration and labeling, including the exact dose strengths and therapeutic indications approved for that market. Without market-specific product registration details, the clinical-trial landscape for “PHENERGAN VC” cannot be mapped to a single global protocol, sponsor, and trial identifier.
What clinical trials are currently active or recently reported for PHENERGAN VC?
A global clinical trials map for the exact branded combination “PHENERGAN VC” cannot be produced from the information available in this session. A complete update requires at minimum: the exact salt form and strength, route of administration, and indication claims tied to a specific regulatory jurisdiction, plus linkage to trial registry entries under the brand name or under the generic combination. No such identifiers were provided.
Is there a definable market for PHENERGAN VC?
Yes at the product-category level, but not at a single, reliable brand-forecast level without market registration, dosing, and sales geography. The category is:
- Promethazine-containing symptomatic medicines (antihistamine and antiemetic use cases)
- Vitamin C combination products marketed for supportive or symptomatic consumption
Market behavior in this category is driven by:
- OTC vs Rx status by country and local substitution rules
- Pricing and pack architecture (syrup/tablet vs injectable; single dose vs multi-dose packs)
- Regulatory labeling for vitamin C claims versus antihistamine indications
- Substitution by other first-generation antihistamines and by second-generation allergy agents where permitted
What does the demand profile look like?
Demand typically correlates with:
- Allergy seasonality (antihistamine demand)
- Nausea-related consumption patterns and pediatric/antiemetic usage practices where promethazine is used
- Vitamin C penetration in retail pharmacies and private-label and generic competition
For market projections, the key variable is the brand’s legal status and reimbursement pathway in each market. Promethazine products often face safety and labeling constraints in certain jurisdictions, which can shift usage toward alternative agents. Vitamin C combinations face heavy generic competition.
Market outlook and projection framework
A credible projection requires:
- Active market geographies where “PHENERGAN VC” is marketed
- Current unit sales (or proxy volume) and channel split (pharmacy chain, independents, hospital, online)
- Price points by pack size
- Regulatory events affecting labeling, sales classification, or supply
No such market operating data is available in this request, so a numeric forecast cannot be constructed without fabricating assumptions.
Competitive landscape: what PHENERGAN VC contends with
At the pharmacology level, PHENERGAN VC competes with:
- Other promethazine formulations (monotherapy or alternative combinations)
- Other antihistamines/antiemetics in the same therapeutic niche
- Vitamin C standalone brands and multi-ingredient immune-support products that capture the “vitamin C” portion of consumer demand
At the commercial level, the dominant competitors are typically:
- Generic promethazine products with similar route and dosage
- Local branded antihistamine/antiemetic products with stronger brand equity
- Retail vitamin C leaders that win on shelf prominence and price
What are the key risks to market growth?
For promethazine-containing products, the market risks are usually:
- Safety and regulatory scrutiny leading to restricted indications, warnings, or tighter prescribing rules
- Substitution to newer antihistamines with more favorable side-effect profiles in allergy indications
- Supply and manufacturing scrutiny when combination products rely on stable vitamin C sourcing and consistent excipient systems
For vitamin C combinations:
- Generic price compression
- Evolving vitamin claim guidance by regulator, limiting promotional differentiation
Key takeaways
- PHENERGAN VC is a promethazine + vitamin C branded product; clinical and commercial performance depends on country-specific registration (dose, route, indication, and Rx/OTC status).
- A global clinical trial update and a brand-specific numeric market projection cannot be produced without product-identity linkage to registries and markets.
- The category faces generic competition and regulatory-driven substitution risks, especially where promethazine restrictions exist.
FAQs
-
Is PHENERGAN VC a new chemical entity?
No. Promethazine and vitamin C are established actives; the brand is a formulation/product-level registration rather than a new molecule.
-
What therapeutic uses drive demand for promethazine products?
Symptomatic relief for allergic-type conditions and antiemetic/nausea use cases, depending on local labeling.
-
Why are vitamin C combinations hard to differentiate commercially?
Vitamin C is widely available as generics and private-label products with aggressive pricing.
-
What typically restricts growth for first-generation antihistamine brands?
Safety labeling, age restrictions, and prescriber preference shifts to alternatives where regulators tighten guidance.
-
Can a numeric market forecast be produced without geography and registration details?
Not reliably; brand-level projections require market-specific sales and regulatory status data.
References
[1] Promethazine hydrochloride product and pharmacology background (general): FDA prescribing information and EMA/UK SmPC public references.
[2] Vitamin C (ascorbic acid) regulatory and usage guidance: FDA/EMA public assessment documents for vitamin C as a nutrient.
[3] Clinical trial registry search methodology (general): ClinicalTrials.gov and WHO ICTRP search frameworks.
